Jeffrey P. George
Jeffrey P. George's purchase track record
Jeffrey P. George has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/27/2026 | LENZ | $50K | -30.7% | -53.4% | +21.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
LENZ Therapeutics faces cash concerns amid low trading levels. A recent analysis highlights LENZ Therapeutics' cash position as a key point of interest for observers. The stock is currently trading near its 52-week low, with an RSI indicating oversold conditions. While analyst targets vary widely, the focus remains on the company's financial liquidity and operational sustainability.
Transaction History
| AMRX | ▲ Buy | Option Exercise | 34,819 | — | 5/7/2026 | View on chart |
| LENZ | ▲ Buy | Open Market | 5,592 | $50K | 3/27/2026 | View on chart |
| MASS | ▲ Buy | Option Exercise | 11,364 | — | 6/11/2025 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 40,258 | — | 5/5/2025 | View on chart |
| MASS | ▲ Buy | Option Exercise | 7,777 | — | 6/12/2024 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 76,453 | — | 5/10/2024 | View on chart |
| MASS | ▲ Buy | Option Exercise | 508 | — | 2/22/2024 | View on chart |
| MASS | ▲ Buy | Option Exercise | 4,771 | — | 6/14/2023 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 80,128 | — | 5/10/2023 | View on chart |
| MASS | ▲ Buy | Option Exercise | 507 | — | 2/22/2023 | View on chart |
| MASS | ▲ Buy | Option Exercise | 1,379 | — | 6/15/2022 | View on chart |
| AMRX | ▲ Buy | Option Exercise | 35,406 | — | 5/8/2022 | View on chart |
| MASS | ▲ Buy | Option Exercise | 508 | — | 2/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
AMRX Gains Fair Value Bump After Analyst Support for New Launches
Analysts have raised AMRX's fair value after backing new product launches, lifting the stock's target range. The company is listed among low‑volatility stocks that still have open questions for investors. The move comes as the shares trade near the middle of their 52‑week range and around the 53.3 RSI level.
AMRX Gains Fair Value Bump After Analyst Support for New Launches. Analysts have raised AMRX's fair value after backing new product launches, lifting the stock's target range. The company is listed among low‑volatility stocks that still have open questions for investors. The move comes as the shares trade near the middle of their 52‑week range and around the 53.3 RSI level.